GlobeNews Wire

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing…

4 days ago

MitoSynergy Introduces BioCopper1 – A Clinically Proven Nutraceutical Designed for Mitochondrial Performance

Scottsdale, AZ, March 24, 2026 (GLOBE NEWSWIRE) -- MitoSynergy, a science-driven wellness company focused on cellular and mitochondrial health, today…

4 days ago

BioSyent Announces Grant of Restricted Share Units

March 24, 2026 17:30 ET  | Source: BioSyent Inc. MISSISSAUGA, Ontario, March 24, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”…

4 days ago

HERE Technologies joins DCSA+ as first mapping and location intelligence partner advancing digital standards in container trade

Amsterdam – HERE Technologies, the leading mapping and location data platform, today announced that it has joined DCSA+, the partnership programme…

5 days ago

ONERugged Vehicle-Mounted Computer V82T Launches to Transform Fleet Management

SHENZHEN, China, March 24, 2026 (GLOBE NEWSWIRE) -- ONERugged, a brand of Emdoor Information Co., Ltd., recently introduced the V82T,…

5 days ago

ConnectingtheWorld,DrivingApexGrowth:ApexmindSummit2026SuccessfullyHeldinHongKong

HongKong, March 24, 2026 (GLOBE NEWSWIRE) -- The Apexmind Summit 2026 was grandly held in Hong Kong today. The summit…

5 days ago

Dupixent (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease…

5 days ago

Idorsia announces the nomination of three candidates for election to the Board of Directors

Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting…

5 days ago

Press Release: Sanofi and Regenerons Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in…

5 days ago

Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer

BASEL, Switzerland, March 23, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with…

6 days ago